Dashboard
1
With a fall in Net Sales of -12.75%, the company declared Very Negative results in Mar 25
- The company has declared negative results for the last 2 consecutive quarters
- The company has declared negative results in Dec 24 after 4 consecutive negative quarters
- OPERATING CASH FLOW(Y) Lowest at CNY 343.73 MM
- INTEREST COVERAGE RATIO(Q) Lowest at 2,661.07
- DEBT-EQUITY RATIO (HY) Highest at -9.33 %
2
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 15,851 Million (Large Cap)
25.00
NA
1.95%
-0.04
8.12%
2.01
Revenue and Profits:
Net Sales:
607 Million
(Quarterly Results - Jun 2025)
Net Profit:
147 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.19%
0%
-10.19%
6 Months
-13.07%
0%
-13.07%
1 Year
-32.03%
0%
-32.03%
2 Years
-4.47%
0%
-4.47%
3 Years
-3.54%
0%
-3.54%
4 Years
-43.4%
0%
-43.4%
5 Years
-48.56%
0%
-48.56%
Pacific Shuanglin Bio-pharmacy Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.60%
EBIT Growth (5y)
30.79%
EBIT to Interest (avg)
51.60
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.30
Tax Ratio
12.64%
Dividend Payout Ratio
37.71%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.78%
ROE (avg)
7.31%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
2.01
EV to EBIT
21.94
EV to EBITDA
18.35
EV to Capital Employed
2.05
EV to Sales
6.24
PEG Ratio
NA
Dividend Yield
1.95%
ROCE (Latest)
9.35%
ROE (Latest)
8.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
606.90
695.60
-12.75%
Operating Profit (PBDIT) excl Other Income
196.10
249.10
-21.28%
Interest
3.50
3.50
Exceptional Items
-3.90
-9.50
58.95%
Consolidate Net Profit
147.00
205.10
-28.33%
Operating Profit Margin (Excl OI)
264.50%
308.80%
-4.43%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -12.75% vs 56.53% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -28.33% vs 136.29% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,632.60
2,307.00
14.11%
Operating Profit (PBDIT) excl Other Income
929.10
781.00
18.96%
Interest
11.20
10.00
12.00%
Exceptional Items
6.60
-19.00
134.74%
Consolidate Net Profit
745.00
611.50
21.83%
Operating Profit Margin (Excl OI)
301.30%
275.20%
2.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.11% vs -3.41% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 21.83% vs 4.05% in Dec 2023
About Pacific Shuanglin Bio-pharmacy Co., Ltd. 
Pacific Shuanglin Bio-pharmacy Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






